文献速递前列腺癌

粪便微生物组代谢生物合成通路与前列腺癌的关联

Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-07-12

该研究对105例前列腺穿刺活检前收集的直肠拭子行16S rRNA测序,其中64例确诊前列腺癌、41例无癌。结果显示总群落组成与癌症状态显著相关,癌症组拟杆菌属和链球菌属富集,叶酸和精氨酸通路改变最显著,基于10条异常代谢通路构建的微生物组风险因子AUC为0.64。

要点

  • 前列腺癌与非癌男性肠道菌群多样性总体相似,但群落组成有显著差异。
  • 癌症组拟杆菌属和链球菌属显著富集,叶酸与精氨酸代谢通路改变最显著。
  • 基于10条异常代谢通路的微生物组风险因子AUC为0.64,区分能力有限。

核心结论

  • 肠道微生物组可能对前列腺癌有细微影响,但多具患者特异性,需配对分析和精准干预。

研究设计与样本

  • 前瞻性收集133例直肠拭子,于经直肠前列腺穿刺前2周采集,其中105例完成16S rRNA扩增子测序(64例癌、41例无癌)。
  • 采用PICRUSt推断与分类组成相关的功能类别,p值经错误发现率校正。
  • α和β多样性用QIIME分析,β多样性距离组内与组间比较用Mann-Whitney U检验,通路显著性用LASSO回归分析确定。

主要发现

  • 总群落组成与癌/非癌状态显著相关(Bray-Curtis距离,p<0.01)。
  • 癌症组拟杆菌属和链球菌属富集(均p<0.04)。
  • 叶酸(LDA 3.8)和精氨酸(LDA 4.1)是改变最显著的通路。
  • 基于10条异常代谢通路构建的微生物组风险因子AUC=0.64,p=0.02。

关键数值与推荐

  • 前列腺癌判定依据经直肠前列腺穿刺活检结果。
  • 微生物组谱采用16S rRNA扩增子测序获得。
  • 叶酸通路LDA评分为3.8,精氨酸通路LDA评分为4.1。
  • 微生物组风险因子基于10条异常代谢通路,AUC为0.64,p=0.02。

临床怎么用

  • 微生物组评估可为患者提供特定代谢功能细菌存在与否的个体化数据,提示前列腺癌风险。
  • 该研究为通过调控异常微生物组(如改善天然细菌叶酸产生)降低前列腺癌风险提供了研究基础。

局限性

  • 微生物组对前列腺癌的影响可能细微且具患者特异性,需配对分析验证。
  • 研究基于直肠拭子16S测序与PICRUSt功能推断,非直接代谢物检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The fecal microbiome is associated with prostate cancer risk factors (obesity, inflammation) and can metabolize and produce various products that may influence cancer but have yet to be defined in prostate cancer. OBJECTIVE: To investigate gut bacterial diversity, identify specific metabolic pathways associated with disease, and develop a microbiome risk profile for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: After prospective collection of 133 rectal swab samples 2 wk before the transrectal prostate biopsy, we perform 16S rRNA amplicon sequencing on 105 samples (64 with cancer, 41 without cancer). Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was applied to infer functional categories associated with taxonomic composition. The p values were adjusted using the false discovery rate. The α- and β-diversity analyses were performed using QIIME. The Mann-Whitney U test was employed to evaluate the statistical significance of β-diversity distances within and between groups of interest, and least absolute shrinkage and selection operator (LASSO) regression analysis was used to determine pathway significance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The detection of prostate cancer on transrectal prostate needle biopsy and 16s microbiome profile. RESULTS AND LIMITATIONS: We identified significant associations between total community composition and cancer/non-cancer status (Bray-Curtis distance metric, p<0.01). We identified significant differences in enrichments of Bacteroides and Streptococcus species in cancer (all p<0.04). Folate (LDA 3.8) and arginine (LDA 4.1) were the most significantly altered pathways. We formed a novel microbiome-derived risk factor for prostate cancer based on 10 aberrant metabolic pathways (area under curve=0.64, p=0.02). CONCLUSIONS: Microbiome analyses on men undergoing prostate biopsy noted mostly similar bacterial species diversity among men diagnosed with and without prostate cancer. The microbiome may have subtle influences on prostate cancer but are likely patient-specific and would require paired analysis and precise manipulation, such as improvement of natural bacterial folate production. PATIENT SUMMARY: Microbiome evaluation may provide patients with personalized data regarding the presence or absence of particular bacteria that have metabolic functions and implications regarding prostate cancer risk. The study provides a basis to investigate the manipulation of aberrant microbiomes to reduce prostate cancer risk.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Liss MA, White JR, Goros M, et al. Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. Eur Urol. 2018. PMID: 30007819. doi:10.1016/j.eururo.2018.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。